EPISODE · Feb 26, 2026 · 10 MIN
Biopharma Morning Coffee – Weekly Brief February 26, 2026
Gilead's $7.8B acquisition of Arcellx and its CAR-T therapy anito-cel headlines this week — a PDUFA date of December 2026 signals a major cell therapy outsourcing wave ahead. The FDA also launched its bespoke gene therapy pathway, opening a new regulatory road for gene editing and RNA-based rare disease treatments. Plus: the GLP-1 war heats up as Novo's CagriSema falls to Zepbound, Pfizer licenses a Chinese GLP-1 for $495M, and Astellas bets $1.7B on a masked T-cell engager for prostate cancer.
NOW PLAYING
Biopharma Morning Coffee – Weekly Brief February 26, 2026
No transcript for this episode yet
Similar Episodes
Apr 29, 2026 ·48m
Apr 29, 2026 ·106m
Apr 29, 2026 ·55m
Apr 29, 2026 ·74m